OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2021-04-30-accounts

REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 APRIL 2021

MOVEMBER EUROPE COMPANY NUMBER: 7275694 CHARITY NUMBER ENGLAND & WALES: 1137948 CHARITY NUMBER SCOTLAND: SC041981 CHARITY NUMBER IRELAND: 20105280

1

ANNUAL REPORT 2020

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021

CONTENTS

CONTENTS
Reference and administrative information 1
Trustees’ annual report 2
Independent auditor’s report 27
Statement of fnancial activities (incorporating an income and expenditure account) 31
Balance sheet 32
Statement of cash fows 33
Notes to the fnancial statements 34

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021

REFERENCE AND ADMINISTRATIVE INFORMATION

REFERENCE AND ADMINISTRATIVE INFORMATION
COMPANY NUMBER 7275694
CHARITY NUMBER 1137948 (England & Wales)
SC041981 (Scotland)
20105280 (Ireland)
REGISTERED OFFICE AND Gensurco House
OPERATIONAL ADDRESS 52-54 Rosebery Avenue
LONDON, EC1R 4RP
TRUSTEES Trustees, who are also directors under company law, who served
during the year and up to the date of this report were as follows:
Nicholas Reece (Chairperson)
Paul Villanti (resigned 30 September 2020)
Colleen Nelson (resigned 31 December 2020)
Andrew Gibbins (resigned 11 August 2020)
Kellie Johnston
Simon Traynor
Rob Moodie (appointed 3 October 2020)
Linnsey Caya (appointed 15 October 2020)
Deanna Lomas (appointed 15 October 2020)
Damien Angus (appointed 5 November 2020)
KEY MANAGEMENT PERSONNEL Anne-Cécile Berthier (Country Director – UK & Europe)
Jack O’Connor (Country Manager – Ireland)
Michael Fischer (Country Manager – Europe – left 30 April 2021)
BANKERS JPMorgan Chase
Barclays Bank
25 Bank Street
1 Churchill Place
LONDON, E14 5JP
LONDON, E14 5HP
Lloyds Bank
Santander
25 Gresham Street
2 Triton Square
London, EC2V 7HN
London, NW1 3AN
SOLICITORS Russell Cooke LLP
2 Putney Hill
LONDON, SW15 6AB
AUDITOR Sayer Vincent LLP
Chartered Accountants and Statutory Auditor
Invicta House, 108-114 Golden Lane
LONDON, EC1Y 0TL

1

MOVEMBER ANNUAL REPORT 2021

----- Start of picture text -----
MOVEMBER EUROPE
REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021
----- End of picture text -----

TRUSTEES’ ANNUAL REPORT

The Trustees present their report and the audited financial statements for the year ended 30 April 2021.

Reference and administrative information set out on page 1 forms part of this report. The financial statements comply with current statutory requirements, the memorandum and articles of association, the requirements of a directors’ report as required under company law, and the Statement of Recommended Practice - Accounting and Reporting by Charities: SORP applicable to charities preparing their accounts in accordance with FRS 102.

STRATEGIC REPORT

OBJECTIVES AND ACTIVITIES

The Trustees review the aims, objectives and activities of the charity each year. This report looks at what the charity has achieved and the outcomes of its work in the reporting period. The Trustees report the success of each key activity and the benefits the charity has brought to those groups of people that it is set up to help. The review also helps the trustees ensure the charity’s aims, objectives and activities remained focused on its stated purposes.

The Trustees have referred to the guidance contained in the Charity Commission’s general guidance on public benefit when reviewing the charity’s aims and objectives and in planning its future activities. In particular, the Trustees consider how planned activities will contribute to the aims and objectives that have been set.

Movember Europe aims to have an everlasting impact on the face of men’s health. Annually, the Trustees review the strategic priorities consistent with the organisation’s vision.

2

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 TRUSTEES’ ANNUAL REPORT

WHAT WE DO

We want to help those researchers and practitioners focused on our priority men’s health issues to work together towards common goals to enable them to share resources and knowledge. By eliminating overlap and duplication of effort while allowing more resources to be available, we support and accelerate the development of solutions to complex men’s health problems.

• Understand, promote and advocate for men’s health

By making the community aware of the issues around men’s health, we foster an environment that supports men to take action when it comes to their health and wellbeing. We work across a wide population span and tailor approaches for different groups.

• Build evidence about what works and kick-start sustainable approaches

Movember Europe has invested resources in innovative programmes that have real and long-term impacts on improving how health promotion is delivered, and how systems of treatment and care are delivered. We continually test and evaluate our approaches, share our learnings and undertake research to refine our work. Once we find something that works, we find ways to catalyse its implementation where it can be of greatest benefit, scaling up what works.

• Mobilise men to be more informed, active and connected

Large-scale shifts in complex social problems are best achieved through engaging people across the many environments where they live, learn, work and play. We endorse programmes that find creative and effective ways of supporting men to be proactive about their health care, and to engage with each other about their health and wellbeing.

• Invest in biomedical, clinical and health services research in prostate cancer and testicular cancer

A significant research base that supports long term change can only be achieved by addressing the root causes of how men’s health issues, such as prostate cancer and testicular cancer, arise and the treatments that are available to manage these health issues. Through undertaking and investing in research, we are actively contributing to the search for breakthrough knowledge that accelerates improvements in targeted men’s health issues. We need to find answers to the key scientific and clinical questions that will lead to men living, and not dying from prostate or testicular cancer, and living long, quality lives. Through investing in research, we are making a powerful global contribution to finding those answers and accelerating improvement in these health issues.

FUNDRAISING STRATEGY

The result that we seek to achieve through our fundraising strategy is that we raise sufficient funds to be able to deliver on our strategic programme investments, both existing and future, to help us achieve our vision of having an everlasting impact on the face of men’s health.

Although Movember Europe is supported by year-round fundraising efforts by the Movember community, the annual Movember campaign, held in November, is the primary fundraising initiative for the organisation.

During the month of ‘Movember’, we ask supporters to sign up and fundraise by growing a moustache, taking the Move challenge, Hosting an event or ‘Mo’ing their own way’ through an idea of their own. Through their actions they seek donations (with our peer to peer fundraising model) from their networks and consequently not only raise funds but also importantly help spread the organisation’s health messages to their family, friends and colleagues.

3

MOVEMBER ANNUAL REPORT 2021

----- Start of picture text -----
MOVEMBER EUROPE
REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021
TRUSTEES’ ANNUAL REPORT
----- End of picture text -----

INVESTMENT STRATEGY

Movember invests in four priority areas that represent significant challenge and that will impact men’s wellbeing: prostate cancer, testicular cancer, mental health and suicide prevention, and men’s health promotion.

PROSTATE CANCER

The result we seek to achieve for men living with and beyond a prostate cancer diagnosis is to ensure access to the treatment and care needed to be physically and mentally well.

Through our education, awareness and investments, we seek to make a significant contribution to reducing prostate cancer mortality and improving health outcomes and quality of life for men diagnosed and living with prostate cancer.

We seek to achieve this by investing in biomedical, translational, clinical, health services, quality improvement and education initiatives that will:

4

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 TRUSTEES’ ANNUAL REPORT

TESTICULAR CANCER

The result that we seek to achieve is that men and boys living with and beyond testicular cancer have access to the information, resources, treatment and care they need to be physically and mentally well. We aim to invest in:

Biomedical, translational, clinical, health services, care and education initiatives that will:

Health outcomes research and initiatives that:

MENTAL HEALTH AND SUICIDE PREVENTION

The results that we seek to achieve are to contribute to boys and men having improved mental health and wellbeing and a decreased rate of suicide.

We fund and deliver programmes that lead to men staying mentally well, being socially connected, having meaningful conversations and taking action during tough times.

Our programme investments include:

MEN’S HEALTH PROMOTION

Our Health Promotion Plans address the following challenges consistent across all of our cause areas:

The need for men to:

5

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 TRUSTEES’ ANNUAL REPORT

ACHIEVEMENTS AND PERFORMANCE

The charity’s main activities and who it tries to help are described below. All its charitable activities focus on men’s health and are undertaken to further Movember Europe’s charitable purposes for the public benefit.

The table below presents the major initiatives Movember continues to fund in the UK, along with a summary of key achievements and performance of programmes.

----- Start of picture text -----
PROJECT ACHIEVEMENTS
----- End of picture text -----

True North (UK) True North is a collaborative partnership of leading UK prostate cancer clinicians and researchers
who have been delivering a number of highly innovative care initiatives aimed to signifcantly improve
health outcomes for men with prostate cancer. The initiative drew to a close in January 2021, with
a review undertaken to document learnings, knowledge generated and scaling considerations from
the 8 priority initiatives: Continence Management, Exercise and Diet, Electronic Holistic Needs
Assessment and Care Planning, Post Radiation – EAGLE Study, Post-surgery, Maximising Sexual
Wellbeing, Supported Self-Management, Decision Support: Understanding Consequences. We are
now planning to scale the most promising initiatives in the next phase of the programme.
Prostate Cancer We support national and international initiatives that aim to reduce variation in treatment quality
Clinical Quality across all stages of prostate cancer. The TrueNTH Global Registry and Ironman Registries involve
clinical sites across the UK. These programmes measure, benchmark and improve the quality of
prostate cancer treatment and care.
Belfast-Manchester Belfast-Manchester Centre of Excellence brings together an international team of experts in
Centre of radiation, biomarker discovery, genetic modelling and tumour biology in the FASTMAN programme
Excellence that aims to improve the effectiveness of treatment for men with high-risk, locally advanced
prostate cancers and prevent disease recurrence (progression to metastatic disease).
Centres of London Centre of Excellence has improved diagnostic tests including the better use of magnetic
Excellence resonance imaging that allows more accurate detection of small volume tumours, as well as tissue-
– London and blood-based biomarkers that can be used to identify men at high risk of aggressive disease and
Consortium so allow better treatment choices based on each man’s genetic information.
Translational
Research Awards		 These Awards fund translational research projects that take early-stage, basic discoveries a step
closer to making tangible improvements for men affected by prostate cancer, with specifc focus
on identifying men at high risk of developing aggressive disease and developing new, targeted
treatment for advanced disease.
Precision Medicine The primary focus of this programme is to obtain the evidence required to support novel biomarker-
Awards treatment pairings for men newly diagnosed with advanced prostate cancer. It is proposed that by
developing a better understanding of the specifc drivers of a man’s disease (i.e. precision medicine), it
may be possible to identify the treatment that they are most likely to respond to and improve outcomes.
Research This programme aims to support the most impactful and innovative proposals across a broad
Innovation Awards spectrum of prostate cancer research areas. Selected projects will approach research questions
from a new angle to generate suffcient evidence in supporting future development of the project.
Existing Trials new The Major Awards looks to utilise and interrogate existing patient samples and/or data from recently
Answers Major completed or ongoing prostate cancer clinical trials, or from other samples and/or data repositories.
Awards Capitalising on these existing resources, the Awards must seek to answer new and innovate research
questions that could lead to signifcant impact in the way prostate cancer is diagnosed or treated.
Global Action Plan In addition to national prostate cancer research programmes, Movember continues to invest in our
Global Action Plan (GAP) programmes. Since 2012, Movember has established seven consortia that
foster international collaboration in translational research to address critical challenges in prostate
and testicular cancer.

6

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 TRUSTEES’ ANNUAL REPORT

----- Start of picture text -----
PROJECT ACHIEVEMENTS
----- End of picture text -----

Health Promotion A core part of our Movember Europe activity is the work we do to empower men with the awareness,
knowledge, and resources to take positive action for their health and make it possible for them to
achieve their fullest life potential. This is delivered through our Health Promotion programme.
Mass media Reach and engage younger, lower income men with mass-media content and messaging that
behaviour change promotes healthy masculinity and healthy behaviours.
Testicular Cancer We support international and national biomedical research and survivorship initiatives of which UK
men and clinicians make an important contribution.
Social Innovators
Challenge		 The Social Innovators Challenge (SIC) is tackling the hidden problem of male social dis-
connectedness, which research has shown can have a signifcant impact on the health of men,
leading to increased risk of suicide, depression and anxiety. The Challenge asked people to submit
their idea to address men’s loneliness and isolation by restoring and strengthening men’s social
connections and sense of belonging. Four projects have been funded that are currently underway. The
programme is currently in Phase 3 – Scaling and extended piloting which will occur from 2020-2023.
Ahead of the Game Ahead of the Game is a community-based programme that uses sport to teach athletes, parents
and coaches how to talk about mental health.
Movember Family
Man		 Movember’s Family Man is a parenting programme designed to equip parents with the skills and
tools they need to deal with diffcult behaviour in kids aged 2-8; and to do it in ways that strengthen
and unite the family. Family Man focuses on engaging and motivating dads to be more active and
involved in parenting decisions, supported by a huge amount of research that tells us parenting is
far more effective when done as a team.
Movember Movember Conversations gives users the confdence to have conversations with the men in their
Conversations life who might be struggling. Based on the ALEC framework designed by R U OK?, Movember
Conversations offers the tools needed to start a conversation, to be a good listener and to create a
setting of trust and openness.

7

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 TRUSTEES’ ANNUAL REPORT

ACHIEVEMENTS & PROGRESS

CENTRES OF EXCELLENCE

The transformative nature of the investment made into the two Movember Centres of Excellence is already evident at this early stage:

The London Centre of Excellence is pursuing research to improve the diagnosis, management and treatment of prostate cancer through personalised precision medicine approaches to improve clinical care. The programme has focused on (1) identifying risk factors for aggressive prostate cancer for targeted screening approaches, (2) developing germline and tumour biomarkers related to primary treatment resistance and/or sensitivity in locally advanced disease and (3) qualifying biomarkers to enable better treatment and outcomes for aggressive prostate cancer. Key highlights from this programme include:

The London programme has been granted a no-cost extension until June 2023.

The Belfast-Manchester Centre of Excellence has enabled the development of a large multidisciplinary team of research experts, many of whom were new to the prostate cancer field, to focus on a central hypothesis addressed through a number of linked work packages within this comprehensive radiotherapy-focused research programme for men with locally-advanced prostate cancer. The establishment of the Centre has transformed prostate cancer research in Belfast and Manchester and it is currently in the third phase of the programme, which aimed to build upon the momentum from past years, with the original FASTMAN programme further separated into three major thematic programmes:

1. Tissue based discovery leading to biomarkers of distinct biology linked to radiotherapy resistance, including (1) the Metastatic Biology Assay, (2) the DDRD assay and (3) the Hypoxia Assay. This programme also led to the initiation of innovative, biomarker-guided, biologically-informed clinical trials aimed at optimising the use of DNA-damage therapy in high-risk prostate cancer, including (1) ADDRAD trial and (2) SPORT clinical trial. The FASTMAN work has also formed the basis for the Biomedical Imaging Group Repository, which contains more than 5,000 scans linked to outcome as a key plank of the STAMPEDE trial programme.

8

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 TRUSTEES’ ANNUAL REPORT

2. Understanding genetic and biological drivers of radiotherapy relapse through comprehensive genomic, epigenomic and transcriptomic profiling on multiparametric magnetic resonance imaging visible and invisible lesions of prostate cancer presenting with multifocal disease. This programme also established and characterised advanced models (biopsy- and mouse tumour-derived cell lines) of high-risk prostate cancer, which can be used to model the biological and immunological response of high-risk disease to ionising radiation. Through the SPORT trial, the team also aim to characterise the impact of fractionation schedule in radiotherapy in response to PTEN status as a biomarker.

3. Understanding use of radiation in treatment of advanced disease that have led further investigation into the alphaparticle radiation effect of radium-223 as well as therapeutic mechanisms to enhance DNA-damage therapy. The team is also in discussion with the STAMPEDE Trial Management Team to progress the hypoxia 28-gene signature-driven trial to the STAMPEDE trial.

The Belfast-Manchester programme is expected to be completed by June 2022.

TRANSLATIONAL RESEARCH AWARDS

It has been estimated that, on average, it takes 17 years for any research discovery made in the lab to have a tangible impact in the forms of new treatments and/or diagnostic tools that will make a difference to men with prostate cancer. This programme aims to accelerate this process by building on previously funded early discovery research that has real potential to make the leap from bench to bedside.

Two research calls were made in 2014 and 2015 and a total of six projects were funded as part of this scheme:

1. There is growing evidence in the epidemiologic context to suggest that the use of statins post-diagnosis positively impacts on the outcome of patients with lethal prostate cancer. It has also been suggested that decreasing cholesterol bioavailability suppresses the growth of advanced prostate cancer. Dr Leung initiated a single-arm phase II trial in men with early evidence of castrate-resistant prostate cancer (CRPC) to test the impact of combined antigen deprivation therapy (ADT) and atorvastatin in disease progression, using PSA response as a surrogate biomarker. As expected, atorvastatin was very well tolerated with minimal reported adverse side-effects and reported evidence of CRPC disease stabilisation following statin treatment and identified a candidate serum metabolic signature of tumour response.

2. Bone disease is common in men with metastatic castrate-resistant prostate cancer, which results in significant morbidity and mortality. There are now a number of effective drugs that can relieve pain, prevent skeletal complications and prolong life. However, current imaging techniques are suboptimal in identifying which patients are benefiting or worsening with treatment. Dr Koh’s research in a pilot study has confirmed the utility of total tumour volume and global apparent diffusion coefficient as markers of treatment response. These markers are currently being tested in a multi-centre UK study funded by the NIHR, together with the development of a commercial software to support image analysis.

3. The level of oxygen in a tumour is an important factor that affects whether a man will be cured of their prostate cancer. Dr Choudhury set out to develop a hypoxia gene signature for selecting patients with aggressive prostate cancer and poor prognosis who should benefit from hypoxia-modifying treatment. The team has successfully identified a list of genes that could be used in a test – a 28-gene signature. Furthermore, the team developed a way to measure the level of this signature from prostate cancer biopsies and is seeking funding to use this signature in a randomised biomarker-driven clinical trial (potentially as an arm of STAMPEDE).

4. Multiparametric magnetic resonance imaging (mpMRI) is an important tool for cancer diagnosis but using it on all men with suspected prostate cancer would be very expensive for the NHS. In the INNOVATE trial, Dr Whitaker looked to identify men who will benefit from diagnostic mpMRI before biopsy and how the performance of the mpMRI itself can be improved by imaging the prostate in greater detail to improve the diagnosis of aggressive disease but also help to reduce the number of men undergoing unnecessary biopsies. The trial database has been ‘locked’ to allow cross cutting comparisons and future work will involve validation of the most clinically relevant results in a multicentre study – initial analysis suggests that MSMB in particular might prove useful in differentiating those patients that require a biopsy from those that do not.

5. Dr Attard initiated the PARADIGM study, which aims to verify the original research finding which shows that men with a rising PSA after first-line hormone therapy and who have increased copies (i.e. abnormal) of androgen receptor genes will have little benefit from abiraterone or enzalutamide treatment. Instead, they will have better tumour responses and outcomes with chemotherapy. The trial is expected to complete the recruitment of 170 men by October 2021 with additional 5-year follow up from the date of the first patient registration. If successful, this project will lead to a change in clinical practice whereby selection of chemotherapy versus hormone treatment is informed by a molecular blood-based test that identifies abiraterone / enzalutamide resistant tumour clones.

9

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 TRUSTEES’ ANNUAL REPORT

6. Dr Feber and his team aims to validate a non-invasive, cell-free DNA epigenetic biomarker assay (PACEB) that can rule out the presence of prostate cancer as a replacement for the current PSA testing in the detection and diagnosis of men suspected of having prostate cancer. The team has been evaluating potential techniques that will allow wide implementation of the PACEB test to men in the UK. Meanwhile, a biobank of samples to validate test once the technology has proved effective has been secured – including access to samples collected as part of the Cancer Research UK-funded ReImagine trial. The project is expected to be completed by August 2021.

While some of the projects are still ongoing, this programme has so far generated 15 publications with over 200 citations and leveraged approximately £6.4m on the back of Movember’s investment (£2.6m).

PRECISION MEDICINE AWARDS

Despite recent advances in the treatment of lethal prostate cancer with the successful development of numerous new treatments, metastatic prostate cancer remains incurable, and many thousands of men continue to suffer and die from this disease. It has been proposed that the inter-patient molecular heterogeneity of this disease is partly responsible for the late and costly failure of many large-scale, randomised Phase III trials. Clinicians are currently left to treat patients ‘in the dark’ with little idea as to which treatment will work best for which men. The Precision Medicine programme therefore aims to support the optimisation of biomarker assessment in order to inform precision-treatment selection for men with advanced disease. Two projects have been funded under this programme:

1. Evidence from the STAMPEDE and CHAARTED trials has shown that treatments given earlier, when men are starting longterm hormone treatment, are more effective in delaying time to progression with men living a longer life. With specific focus on men diagnosed with metastatic disease but who have yet to develop resistance to hormone therapy, Dr Attard established the pan-UK STRATOSPhere consortium, which aims to develop a framework of biomarker development and therapeutic target validation that will lead to the successful introduction of novel biomarker-treatment pairings within the STAMPEDE trial platform – the team has secured industry support and is developing a protocol for opening a PARP inhibitor trial arm in 2021.

2. Dr de Bono’s project aims to molecularly stratify lethal prostate cancer at diagnosis to allow better care for individual men based on precise detection of hijacked aberrations that have led to this disease pathogenesis. The team set up the MAESTRO trial for molecular characterisation of lethal prostate cancer biopsies using next generation sequencing with orthogonal validation in post-chemotherapy setting to evaluate concordance of biomarkers and key clinical parameters. In addition, the team also started a multi-arm PERSEUS trial and commenced screening of men to the first arm of the trial, which aims to determine the efficacy of Pembrolizumab in men suffering from lethal prostate cancer with high mutational load and/or MSI and/or a DNA repair defect including MMR deficiency after progression on standard therapy. The project is ongoing with expected completion by October 2022.

RESEARCH INNOVATION AWARDS

The Research Innovation Awards encourage innovative proposals across a broad spectrum of prostate cancer research areas, where both fundamental and clinical research (and all stages in between) would be considered if they have a clear focus on the eventual benefit to men. Two projects have been funded under this programme:

1. Despite robust responses to abiraterone and enzalutamide which target the antigen receptor (AR) signalling, men with advanced disease inevitably progressed to lethal, endocrine-resistant prostate cancer with persistent AR signalling. Novel therapeutic strategy blocking mechanisms driving persistent AR signalling are now urgently needed. Previous work from Professor de Bono’s team has shown heat-shock factor-1 (HSF-1) inhibitor was able to disrupt the androgen receptor signalling pathway and inhibit the growth of enzalutamide-resistant prostate cancer cell lines and patientderived organoid models. This project therefore aims to further validate the potential of the HSF-1 inhibitor as a novel treatment strategy using in vitro models and, if successful, progress the safety and efficacy research in clinical trials. The project commenced in September 2019 and is expected to be completed by September 2022.

2. Progression of prostate cancer is highly heterogenous, with risk assessment at the time of diagnosis considered as a critical step in the management of this disease. Sampling issues associated with needle biopsy have prompted the development of non-invasive urine tests for aggressive disease. Based on his research finding as part of the Movember GAP1 Biomarker Initiative, Professor Cooper’s team has developed the Prostate Urine Risk (PUR) test that can distinguish men on active surveillance whose disease has progressed and should be considered for active treatment. The team will prospectively validate the test as well as the utility of an at-home urine sample collection protocol, with over 2,000 men across 10 sites in UK, Ireland, Italy, Germany and Canada. The project commenced in October 2020 and is expected to be completed by January 2023.

10

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 TRUSTEES’ ANNUAL REPORT

MAJOR AWARDS: EXISTING TRIALS, NEW ANSWERS

Over the past decade, many clinical trials have and are taking place internationally to change the way prostate cancer is diagnosed and treated. Many of these trials have not only produced practice-changing results but also amassed large quantities of clinical data and patient samples which hold huge potential to help the research community in investigating a number of unanswered questions. This programme was therefore established with the aim to utilise and interrogate existing patient samples and/or data from recently completed or ongoing prostate cancer clinical trials, or from other sample / data repositories, to answer new and innovative questions that could significantly improve the outcomes of men with prostate cancer. Three projects have been funded under this programme:

1. Prostate cancer can take significant time to progress to lethal disease and does so in a subset of cases for which typical risk nomograms (age, PSA, Gleason Grade) are inadequate predictors. Recent advances in imaging such as mpMRI have enriched intermediate and high Gleason Grade disease at biopsy but failed to resolve the challenges of predicting hard clinical endpoints such as lethality from the disease, which requires new data in patients with sufficient length of follow-up and known outcomes, as well as the application of artificial intelligence to identify and analyse these data in new spatial and clinical contexts. Professor Hamdy and Professor Mills hypothesised that there are occult cellular, glandular and morphological features in diagnostic biopsies that reflect the underlying presence of molecular drivers of lethal prostate cancer. Their team aims to conduct a comprehensive image analysis of specimens collected from both mature prospective trials and currently recruiting trials in establishing a code / fingerprint for lethal prostate cancer.

2. Prostate cancer is highly heterogeneous where 30% of advanced prostate cancers have defective DNA damage repair (DDR) response that associates with aggressive disease that are therefore susceptible to PARP inhibitors and immunotherapies. Professor de Bono’s team has led the adaptive trial that treated 140 men with advanced prostate cancers with olaparib and demonstrated antitumour activity against cancers with DDR defects. In this project, he will utilise the tumour biopsies, serial cfDNA and CTC samples collected from this trial to understand why some prostate cancers with DDR defects do not respond to PARP inhibitor and establish circulating biomarkers from serial blood tests that can be used to determine treatment response and identify prostate cancers that are sensitive / resistant to PARP inhibitors.

3. Intensification of androgen receptor targeting by addition of anti-androgens like abiraterone to androgen deprivation therapy (ADT) for metastatic, hormone-sensitive prostate cancer (mHSPC) is highly effective. While the survival benefit remains to be determined, this treatment strategy has also been shown to prolong time to relapse in high-risk, locally advanced, non-metastatic prostate cancer. Professor Attard and his team hypothesise that treatment intensification with anti-androgens will improve outcome of a sub-group of high-risk, locally advanced prostate cancer patients receiving ADT and radiotherapy, however, this will only be cost effective with best improvements in patient quality of life when a molecular test is used to direct such treatment decisions. This project aims to use detailed copy number profiling on cancer-enriched regions from diagnostic biopsies in the STAMPEDE tumour biobank to discover and validate prognostic signatures for high-risk, locally advanced prostate cancer patients starting ADT and considering addition of potent antiandrogens.

These projects commenced or will commence at various time points between October 2020 and October 2021, and first annual progress reports will be received between December 2021 and December 2022.

11

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 TRUSTEES’ ANNUAL REPORT

TRUE NORTH UK

CONTINENCE MANAGEMENT

The continence boxer shorts, developed as part of the programme are in the early stages of prototype development for commercialisation and mass production pending further trials. This commercialisation may generate royalty payments to those organisations involved in the research study.

SUPPORTED SELF-MANAGEMENT

The supported self-management (SSM) project has attracted significant interest across the UK and Ireland. The results showed that physical health outcomes for men receiving supported self-management were similar to usual care. Men receiving supported self-management reported small but significant improvements in quality of life and reductions in unmet needs compared with usual care. The new model of follow up was perceived by men and the clinical team to have improved the quality of provision for follow up.

In addition, clinical time was re-apportioned, with clinicians spending more time with complex patients. The evaluation also stated that supported self-management was perceived to have improved the safety of follow-up care due to the robust callrecall system, PSA tracker and increased staff capacity to support men to comply with PSA testing schedules.

The pathway is now provided as an example in NHS England guidance on implementation of personalised stratified follow up and supported by the NHS England plans. We are working in collaboration with a number of Cancer Alliances across England supporting the implementation of the True North SSM across the NHS trusts they represent.

In addition, the pathway is the accepted model of follow up across Wales along with working with one of the three Cancer Networks in Scotland to implement SSM across their locality. The model was presented to the National Cancer Control Programme in the Republic of Ireland.

MAXIMISING SEXUAL WELLBEING

The True North Sexual Wellbeing project completed its pilot efforts in December 2019. Evaluation of the sexual health selfmanagement resource showed that men experienced statistically significant increases in both their:

In qualitative feedback, men reported feeling isolated in their experiences of sexual wellbeing challenges due to prostate cancer prior to using the resource but found that the resource helped to normalise their experience. The evaluation found the programme to be flexible and relevant to a mixed audience in terms of treatment, sexual orientation and relationship status.

To support the scaling phase, we are promoting the health care professional training package through Prostate Cancer UKs health care professional network and disseminating the online self-management programme to men and partners through our specialist nurses and patient online forum.

POST-SURGERY

The True North UK Post-Surgery Project successfully collected clinical and patient reported data across 26 hospitals in the UK with publication of initial outcomes in BMJ Open 2020 Nov 14;10(11).

The project conducted a review of validated patient reported outcome measures prior to questionnaire design. The gathering of data was implemented through incorporating PROMS into the My Medical Record system (also used in Supported SelfManagement). In phase I, 429 men were recruited across 9 centres. After considering phase I results and determining that existing measures (EPIC and STAR) did not adequately capture data on urinary and sexual functions, qualitative work was carried out and an adapted version of the STAR instrument was established. In Phase II, 1,636 men registered for the study across 26 centres. Data was captured pre-operation and then 1, 3, 6 and 12 months following surgery. Clinical data was also available for a number of men who participated. At the conclusion of the study clinical data had been completed for 1,168 men and data for both 12 months surveys and clinical data was available for 768 men. Collection of data continued beyond the funding period of the project and work including clinical data collection continued into the first quarter of 2021, with an intention to conduct further analysis with a more complete dataset.

12

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 TRUSTEES’ ANNUAL REPORT

MOVEMBER’S GLOBAL ACTION PLAN

GAP4 – EXERCISE AND METABOLIC HEALTH IN PROSTATE CANCER

Through a global collaboration of participating clinical study sites, GAP4 will execute a large-scale, multi-centre, multinational pivotal clinical trial designed to test the effects of exercise on prostate cancer progression. Specifically, the GAP4 Project will determine if supervised intense exercise and psychosocial support increases patient survival compared to selfdirected exercise and psychosocial support in men with metastatic prostate cancer.

The aim is for 866 men to be recruited into the trial (433 randomised to supervised exercise and 433 randomised to selfdirected exercise) across approximately 30 clinical sites globally, with 5 sites currently identified in the UK. Each clinical site will have a multi-disciplinary team of oncologists, exercise physiologists and study coordinators who will recruit the men and facilitate their exercise regimen. Guys & St Thomas’s NHS Trust have been engaged to act as the local sponsor and coordinating lead site for the UK tasked with preparing all UK sites for opening. The 5 UK sites are:

GAP6 – OLIGOMETASTATIC PROSTATE CANCER PROJECT

The GAP6 project in oligometastatic prostate cancer is focused on identifying and confirming the biology of disease that has spread outside of the prostate but only to a limited number of sites. As imaging methodologies improve, so does the sensitivity with which we can detect disease within the body, and there is the potential that men with early metastatic disease who were once thought incurable could now be cured with focal and curative therapies. The project is a collaborative effort that builds on existing clinical trials in several countries with a biologically focused translational science project. The project is now in the sample collection phase and the first rounds of sequencing on two out of three projects is underway.

OTHER PROGRAMMES

TESTICULAR CANCER: THE TIGER TRIAL

Movember is funding the European and Australian contribution to a large, multi-national clinical trial investigating the impact of high dose chemotherapy against conventional chemotherapy on overall survival and quality of life in men who have failed first line chemotherapy for relapsing testicular cancer. This trial is a large scale, multi-national effort in a particularly rare patient population. The trial is managed in the US and Canada by the Alliance for Clinical Trials in Oncology and funded by the NCI.

The European and Australian contribution will be managed by the European Organisation for Research and Treatment of Cancer (EORTC) and Australian and New Zealand Urogenital and Prostate Clinical Trials Group (ANZUP) respectively and funded by Movember.

To date, the EORTC have opened the TIGER trial in 31 sites across 10 countries throughout Europe and have recruited 200 men to the trial. The ANZUP team have opened the trial in Australia and have accrued a further 11 patients.

The sites participating in the TIGER trial from the UK are:

13 MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 TRUSTEES’ ANNUAL REPORT

MEN’S HEALTH PROMOTION

Our Health Promotion strategy seeks to improve the health outcomes of vulnerable men, at scale, and contribute to the reduction in the number of men dying too young. Through the use of media and communication we aim to create positive behaviour change.

The Health Promotion work in 2020/21 operated at two levels. Firstly during the Movember campaign, we ask supporters to sign up and fundraise by growing a moustache, taking the Move challenge, or hosting an event. Their actions not only raise funds but also equally importantly deliver on our awareness and education objectives, to raise awareness and understanding of the health risks men face and result in men taking action to remain well.

Secondly, our work in the UK this year was targeted at a population group, which we established early into the COVID-19 pandemic in 2020 were likely to be disproportionately affected: young men, aged 16-19, from lower SEC backgrounds. The work was informed and designed in conjunction with an in-depth research project that spanned three countries, over nine months using innovative methods to build our understanding of the lived experience of our target groups of men, as they faced this significantly challenging moment.

The work of the Health Promotions team included a campaign using UK Influencers delivered via YouTube, and a research undertaking that culminates in a final report, due for external release in the second half of 2021.

CAMPAIGN: UK INFLUENCER

A pilot initiative to build on our existing evidence, that mass media interventions can effect change, we looked to move the target audience:

From: Young men feeling emotionally trapped, fearful to appear vulnerable in front of their mates and unable to reach out for support.

To: Young men feeling confident to express emotion and reach out to their mates to share feelings and seek support.

The idea was to use the existing influencers that our audience love, from across cultures to role model what emotional vulnerability looks like. We commissioned these influencers to make videos in their own style, that encourage men to be more open and emotionally vulnerable with their mates, especially when they are finding things tough. Using behaviour change techniques such as modelling, encouraging reflection and making this socially permissible. The format and style were decided by each influencer, allowing us to trial contact that had real emotional sincerity and content that used humour to deliver the messaging. Whilst Movember was acknowledged in the content, the message and format are ‘owned’ by the influencer.

Eighteen short form content pieces (10-22mins) were created in partnership with these influencers and then shared on the influencers’ owned distribution channels, largely via YouTube and Instagram.

In this way we were going directly to where this target audience of young men already were, following their trusted and engaging influencers, on platforms where they were spending large swathes of time.

The campaign reached an audience of just over 8.1million, with more than 650k online engagements on the influencers’ channels. Subscribers of the influencers that engaged with this content were more likely to show improved knowledge of the value of open, vulnerable conversations and were more likely to ask for support from a friend than non-subscribers, indicating an intention to seek help.

“This is the content I’ve wanted from this group … proper chats with nothing off the table”

“This video got me. Big respects to Deji for opening up and this video taught me to open up about my feelings and in overall being myself. Thankyou x”

Key insights from the work show us that whilst mental health is well established as a concept with these young men and they know how to help the people around them, they’re less willing to open up and ask for support themselves. Social media and YouTube consumption dominates, and traditional masculinity is outdated, but ‘lad’ culture is pervasive in their media diets and popular culture. This pilot activity in 2020 shows early signs of cutting through, with this hard to reach and at-risk audience for relatively low acquisition cost and early indicators of engagement and willingness to take action. Our work in 2021/22 will build on these learnings and this method to go further with this audience along our behaviour change framework, into deeper engagement and action taking, to move us toward long term change.

14

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 TRUSTEES’ ANNUAL REPORT

THE LISTEN AND LEARN PROJECT

Recognising that younger men would be at significant risk of poor health outcomes as a result of the pandemic and looking to design behaviour change work that was rooted in culture and delivered through media, the health promotion team commissioned a significant piece of research to ensure we were led by the voices and experience of the men we seek to support.

The research was commissioned by Movember and conducted by The Good Side, a UK-based insights and social change agency. The quantitative survey was conducted over two waves in November 2020 and January 2021, with a total of 3,000 men surveyed representative of the national population in the UK (1,000 men), Canada (1,000 men) and Australia (1,000 men). In addition, 800 men identified as representing target audiences for Movember’s media intervention work were included in the survey. This comprised 200 men aged 16-19 years in the UK living in households with an income of less than £40,000, 400 men aged 18-34 years in Canada living in households with an income of less than $70,000 and 200 men aged 16-24 years in Australia living in households with an income of less than $50,000.

The 20-minute survey asked men about their mental health during COVID-19, and explored themes around relationships, social connection, loneliness, dealing with pressures during COVID-19, masculinity in today’s world and outlook for the future.

The project also involved an innovative qualitative study known as The Field, a specially designed online community for men to openly share their views and experiences relating to mental health. Involving 52 target audience men from the UK, 32 men from Canada and 30 in Australia, the Field was developed to reflect the real-life places men go to talk, hang out with peers, and feel supported. Questions, activities, and polls were posted on The Field to explore themes around mental health, relationships and how men are coping with the challenges presented by COVID-19. Through The Field, which was live from July 2020 to January 2021 in Canada and the UK, and March 2021 to April 2021 in Australia, Movember gathered insights to help shape its approach to media interventions targeting these groups of men in each country.

The findings of the work were extensive and will be provided for wider dissemination in the latter half of 2021 in a report. At a high level our audience findings included:

1.FUTURES ARE NOT FELT EQUALLY: THE LINK BETWEEN INSECURITY, INEQUALITY AND MENTAL HEALTH ARE SIGNIFICANT.

69% of men agree that ‘Overall, men’s mental health is worse today than it has ever been before’ - rising to 79% of young, less affluent men.

65% of men agree that ‘Living through COVID-19 may change my life forever’ - rising to 75% of young, less affluent men. 52% of men agree that ‘Living through COVID-19 may change my mental health forever’ - rising to 67% of young, less affluent men.

Distress peaks in youth: Young and less affluent men are hardest hit, especially the very youngest. 3 in 4 of the 16–19-yearold UK target reported high or very high distress, with only 1 in 20 reporting low distress. A second validated scale, the Kessler-10, was used alongside the WHO-5 to assess levels of immediate anxiety and distress and reinforced the pressure on young and less affluent men.

2. MASCULINITY PERCEPTION GAP: OUR YOUNG MEN DON’T AGREE WITH REGRESSIVE MASCULINE NORMS, BUT THEIR LIVES ARE STILL SHAPED BY THEM.

Our investigation with 3,800 men across the UK, Canada and Australia found 3 in 4 personally disagree with regressive views about masculinity - and the vast majority strongly disagree with them.

And whilst men consistently held personal views about masculinity that are more progressive than the views they see furthered in society (this difference between societal perceptions and personal views is the ‘perception gap’), it means men feel pressure to live up to social norms they don’t want or agree with.

53% of young, less affluent men agree that ‘I cannot be my true self because of society’s judgements and expectations of men’ – compared to 37% of Nationally Representative men.

15

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 TRUSTEES’ ANNUAL REPORT

3. MASCULINITY FEELS BEYOND THESE MEN’S CONTROL: OUR YOUNG MEN NEED TO BE ABLE TO TAKE AN EMPOWERING STAKE AND ENGAGE IN THE GENDER DEBATE.

54% of men agree ‘It’s hard to ‘do the right thing’ as a man in today’s world’ - rising to 64% of young, less affluent men. 61% of men agree ‘Being a man in 2020 is more difficult and complicated than it was for previous generations’ - equal to young, less affluent men.

In the post-pandemic world, we cannot talk about ‘men’ as one homogenous group. The experiences of younger, less affluent men are different to the wider population, and they are more likely to be experiencing poor wellbeing and depression and facing higher levels of distress than their more affluent counterparts. From what they see on their social media feeds to when they candidly discuss their own aspirations, men are highly aware of inequality in today’s world, and the majority express significant fears for their future and concerns for their mental health. Media and brands need to challenge assumptions and look beyond broad age ranges and affluent experiences when understanding audiences. The correlation between psychological distress and agreeing with more regressive masculine social norms reinforces the importance of behaviour change initiatives to support young, less affluent men’s mental health and encourage positive norms shifts.

We continue to be guided by the research findings in this project and the voice of the young men we are targeting with the work.

THE MOVEMBER CAMPAIGN

This year during the Movember campaign, we asked supporters to sign up and fundraise by growing a moustache, taking the Move challenge, hosting an event or ‘Mo-ing their own way’ with an idea of their own to fundraise. Their actions not only raise funds but also equally importantly deliver on our awareness and education objectives, to raise awareness and understanding of the health risks men face and result in men taking action to remain well. We undertook a research project to determine whether men who participate in Movember do indeed exhibit the health behaviours we raise awareness and increase education levels around.

“By discussing their (Movember men) moustaches and the unique challenges men face with their health, the moustachioed walking, talking billboards disseminate vital information about prostate cancer wherever they go”. Jepcott et al., (2012)

The Campaign was evaluated and in order to assess the baseline status of defined engagement and action behaviours a survey of Movember participants was conducted, comparing Movember men and a general male population sample recruited by YouGov. Statistical analyses comparing responses from Movember men with those in the general population were then conducted. Attempts to statistically adjust for differences in age, income, and education between the Movember men and the men drawn from YouGov were made. In total there were two timepoints in the study and just over 12,269 respondents across the study.

In comparison with the general male population (and after adjusting for age, education, income, and fundraising status) Movember men were:

These results reinforce the importance of salient, well timed health information presented throughout the month of Movember as men participate and engage with the annual campaign. The more men participating in Movember, the healthier, happier, and potentially longer they will live.

Movember.com continues to be the centralised location for all health promotion content, campaigns, tools, and resources and is regularly reviewed, updated, and built upon.

16

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 TRUSTEES’ ANNUAL REPORT

SOCIAL INNOVATORS CHALLENGE

Four projects from the UK were supported through this programme:

The programme has now moved to Phase 3 – Scaling, however an extended piloting period has been included as some projects had not developed to a point of readiness for scaling. The initiative is continuing to be evaluated by a third-party evaluation team. This team worked with the project teams to develop individual project level evaluation frameworks to increase and strengthen data collection for those projects that are continuing to pilot.

Boxing Futures, Food Nation and Co-Operative & Mutual Solutions are currently in a period of further project development and has been extended over the next 18-24 months. Project teams iterated their delivery models to accommodate social distancing measures during the global pandemic and modified programme delivery plans. The overall goal of this funding however remains the identification of the components of their projects that were successful during two years of piloting, and modification of project plans to strengthen and target the delivery elements and associated activities.

Scottish Association of Mental Health - The Changing Room had a successful 2-year pilot and commenced a three-year scaling of their programme across Scotland through the Scottish Professional Football League teams. Scaling activities to implement over the next 3 years were modified in light of Covid-19 restrictions and moved to online offerings to keep men engaged in the programme. The team developed a ‘playbook’ for the train the trainer component of the programme to ensure programme fidelity during programme delivery. The programme will continue to include evaluation activities that measure improvements in social connectedness as well as whether the programme is able to achieve the same outcomes in scaled form.

TRUENTH GLOBAL REGISTRY

Operating internationally across 13 countries, the TrueNTH Global Registry (TNGR) is a project that aims to significantly improve the physical and mental health of men with prostate cancer. By harnessing new and existing prostate cancer registries and organisations which are systematically collecting clinical data and measuring patient reported outcome measures (PROMs) at baseline and 12 months post treatment, this clinical quality initiative seeks to improve patient outcomes by reducing variation in treatment quality, identifying centres of clinical excellence and providing risk adjusted outcomes data to physicians in the form of Quality Indicator Reports. In the UK there are nine hospitals participating in the project. More information regarding TNGR can be found at https://tngr.movemberhealth.org/

IRONMAN REGISTRY

IRONMAN is an International Registry for Men with Advanced Prostate Cancer recruiting patients over 9 countries. The IRONMAN registry collects information about a man’s type of prostate cancer, their treatment, and their experiences in an effort to understand the disease and learn how to stop or slow disease progression. By collecting clinical information and blood samples periodically from 5,000 men, the registry seeks to understand which treatment and care practices deliver the best outcomes for men with advanced prostate cancer.

The project seeks to:

In the UK, 10 hospitals are participating in the project. More information on the IRONMAN Registry can be found at https://ironmanregistry.org

17

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 TRUSTEES’ ANNUAL REPORT

MOVEMBER FAMILY MAN

In February 2021, Movember successfully launched the world’s first online parenting programme aimed at helping dads (and mums) to improve their child’s behaviour. The free, online course has been designed to equip parents of children, aged between two and eight, with the practical skills to manage challenging child behaviour and increase their own parenting confidence.

A wide body of research shows that parenting interventions are more effective when both parents are involved. Yet, for most parenting programmes, only a fifth (20 per cent) of participants are fathers.

Adapted from a successful evidence-based programme called ParentWorks which was designed by Professor Mark Dadds at the University of Sydney, Family Man has been vetted by a global panel of psychologists and parenting experts.

The results of an open trial of the ParentWorks programme, which was tested on 456 parents and published in the journal of Child Psychiatry & Human Development last year, found significant decreases in parent-reported child emotional and behavioural problems and parental mental health problems in those who took part.

More information can be found at: https://familyman.movember.com/

MOVEMBER CONVERSATIONS

According to Movember’s global Bridging the Distance research report, which looked at the impact of COVID-19 on social connections, almost a third of men said they felt lonely more often than before the outbreak, while nearly a quarter (23 per cent) said their mental health had worsened.

Despite this, a third of men surveyed said they had not checked in with family or friends to find out how they were coping during the crisis.

Movember acknowledges that although maintaining social connections and looking out for each other is key to staying mentally healthy, these conversations can feel uncomfortable and awkward at times.

To address the problem, Movember Conversations, a free interactive digital tool that offers practical guidance on how to start a difficult conversation, was launched in May 2020. Guided by an international team of mental health experts, it uses simulated conversations to explore different scenarios. It demonstrates that changing the way someone responds can lead to deeper, more meaningful conversations.

More information can be found at: https://conversations.movember.com/

AHEAD OF THE GAME

Movember’s Ahead of The Game (AoTG) is a series of mental fitness workshops which have been proven to increase mental health literacy and boost resilience in adolescent athletes who take part.

The evidence-based programme is aimed at adolescents aged between 12-18 and delivered through community sports clubs. During the two-hour workshops, participants learn how to identify signs of anxiety, depression and low mood in themselves and others.

In separate workshops, their parents and sports coaches learn how to distinguish between potential mental health problems and normal teenage behaviour.

The programme was tested by researchers at the University of Wollongong in Australia on 350 boys aged between 12 and 18 across different sports including football, rugby league and swimming, over a season-long period.

Teenagers who took part in the study - the biggest of its kind in the world - demonstrated a better understanding of what mental health is, had greater intentions to help others with a mental health problem and were more confident about seeking help themselves if they needed to.

As official delivery partner for the Rugby League World Cup 2021 - the first ever international sporting event to have a mental health charter - Movember is working with delivery partner Rugby League Cares, to roll out mental fitness workshops to 8,000 teenage rugby league players, their parents, and sports coaches.

Face-to-face workshops, which are delivered by current and former professional athletes, resumed in April 2021, following the lifting of lockdown restrictions in the north of England. Movember also continues to work closely with Rugby Union in the UK, with the Harlequins Foundation rolling out Ahead of The Game across their community clubs.

Following a successful pilot of the programme in football with academy scholars at Brighton FC in 2020, Movember is now working with Fulham FC Foundation to deliver AoTG workshops to 1,500 children across southwest London and Surrey through the Player Pathway Programme, Girls Development Centre, Premier League Kicks, Premier League Inspires and Pan Disability Football Clubs.

18

MOVEMBER ANNUAL REPORT 2021

----- Start of picture text -----
MOVEMBER EUROPE
REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021
TRUSTEES’ ANNUAL REPORT
----- End of picture text -----

FINANCIAL REVIEW

Movember Europe delivered an exceptional result in the year ended 30 April 2021, increasing total income by £8.8 million to a total of £26.9 million. The increase was primarily driven by donation income from our community of Mo Bros and Sisters – through nearly 170,000 registered participants for our 2020 Movember campaign (up from 130,000 in 2019).

Our Ireland branch saw particularly significant growth, with total income increasing from £1.8m in 2019/20 to £4.4m in 2020/21, following an incredible campaign.

Furthermore, revenue from sources outside the annual campaign continues to be significant. Income from Corporate Partners increased to £1.4m (£1.0m in 2019/20), and we saw the first revenue from our Major Gifts function (£131k). The fifth year of the partnership with the Distinguished Gentleman’s Ride generated revenue of £1.1 million, despite needing to move to a solo ride (£2.0 million in 2019/20).

The organisation’s programmatic activity continues to produce outstanding outcomes for men’s health. Movember Europe spent £7.7 million on programme expenditure during the year (£11.5 million in 2019/20) resulting in a net movement in funds of £15.7 million (£3.4 million in 2019/20).

The organisation has set ambitious targets to grow our both our core campaign as well as year- round income streams, and remains committed to funding exciting and innovative projects across the UK and Europe.

19

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 TRUSTEES’ ANNUAL REPORT

PRINCIPAL RISKS AND UNCERTAINTIES

There are three artefacts used together in managing risk at Movember:

The risk register is kept up to date by management and reviewed periodically by the Trustees. Risks given a ‘severe’ or ‘major’ rating are notified to the board with commentary and have been included in the table below alongside a summary of the mitigation plan.

The Trustees are satisfied that the risks of the charity are being sufficiently well managed.

RISK RATING MITIGATION PLAN Dominant news and/or external Severe Movember has proactively sought ways to use our brand and voice events distract attention from the constructively in the face of significant social, economic, and political Movember campaign (e.g. COVIDdisruptions since 2020. 19, political unrest, US Presidential Marketing plans are developed to include contingency plans for election, or a terrorism event) unforeseen events (and lockdown scenarios) that may occur between impacts negatively on campaign late September and early December for each market the Movember fundraising revenue. Campaign runs in.

The Board has a policy to reserve funds annually to ensure operational costs can be met for 9 – 12 months if forecast fundraising targets aren’t met for any reason.

The ability to deliver some of our programmes is impacted, where delivery partners are forced to shut down (or continue to work with restrictions affecting) their physical workspaces while the COVID-19 pandemic remains uncontained.

Major A review of impact on all programmes was conducted in 2020 and mitigation plans to minimise the financial impact of unavoidable delays have been put in place.

Strong dialogue and partnerships with programmatic partners is maintained to understand operational constraints and workarounds.

Opportunities for online delivery of some programmes, especially those with a mental health focus have been identified and pursued where possible. New opportunities for Movember to grow, broaden and deepen its impact, particularly in the area of mental health offerings to combat social isolation and stresses that result from social and economic impacts of the pandemic are also being proactively explored.

20

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 TRUSTEES’ ANNUAL REPORT

RESERVES POLICY AND GOING CONCERN

The unrestricted funds balance for the year ending 30 April 2021 was £34.5 million. Of this balance, £27.5 million has been designated for spend on specific programmes while the balance of £7.0m is retained for general purposes. As the majority of Movember Europe’s revenue is currently derived from one annual campaign, the Movember Europe Trustees have adopted a fiscally conservative approach to risk management; the Board approved Policy requires an accumulation of a general reserves of between 9 and 12 months’ coverage of costs.

The Movember Europe Trustees have elected to maintain a reserves balance equivalent to approximately 10 months of expenditure, or £7.0m, which falls within the Board approved policy. As a result, no further action is required prior to the review of reserves that will take place at the end of the next financial year.

On March 11, 2020, the Covid-19 outbreak was declared a pandemic by the World Health Organisation. Since the first quarter of 2020, the Covid-19 pandemic has been impacting the global economic environment due to government-imposed lockdowns and social distancing requirements. Although the pandemic has had an impact of the operations and activities of Movember Europe, the organisation has been able to maintain a strong financial position and therefore the Trustees believe that the organisation will remain a going concern.

Designated (and restricted) funds have been allocated to the following programmes, and trustees currently expect the majority of this balance to be committed as set out below.

----- Start of picture text -----
PROJECT WITHIN 1 YEAR BETWEEN LATER THAN TOTAL
1 AND 3 YEARS 3 YEARS (MILLION)
----- End of picture text -----

Prostate and Testicular Cancer 2.7 2.3 0.3 5.3
Biomedical Research
Prostate and Testicular Cancer 5.5 6.3 0.5 12.3
Survivorship and Health Outcomes
Mental Health & Suicide Prevention 4.9 3.2 - 8.1
Men’s Health Programmes 2.3 - - 2.3
and Health Promotion
28.0

Funds dedicated to Prostate and Testicular Cancer Biomedical research continue to support existing multi-year projects under Movember’s national and global programmes. National research programmes are being delivered through our partnership with Prostate Cancer UK.

Funds assigned to Prostate and Testicular Cancer Survivorship and Health Outcomes will support ongoing clinical quality and survivorship projects such as the IRONMAN Registry, TrueNTH Global Registry and Nuts and Bolts into years 4, 5 and 6. A large new project, the Global Cancer Real World Evidence Network (RWE), is also being launched which seeks to unify existing Movember funded programmes across the globe and create a network that can support accelerated impact across biomedical research, clinical quality and survivorship. We will continue with and expand our clinical partnerships over the coming years.

Funding for Mental Health and Suicide Prevention programmes will be utilised over the next 12 to 36 months across a broad range of prevention and early intervention programmes. Existing projects will continue to work with their contracted partners through to completion. New projects will work closely with new partners to achieve their programme goals and utilise existing partner expertise as and when applicable.

Funding for Men’s Health Promotion focuses on the continuation and expansion of an existing programme of mass media behaviour change. In the UK our programme collaborates with influencers that engage young men. Based on the positive evaluation results from our initial pilot, we expect to scale and grow this work over the next two years. Movember also intends to develop and launch in Ireland to produce a documentary targeting health behaviour change.

21

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 TRUSTEES’ ANNUAL REPORT

FUNDRAISING POLICY

FUNDRAISING PRACTICES

Movember aims to ensure that all of our fundraising activities are done in an open, honest and compliant manner wherever we operate. In the UK we are a member of the Chartered Institute of Fundraising and voluntarily subscribe to the Fundraising Regulator. This regulator has been responsible, since July 2016, for overseeing an independent and voluntary system of regulation of fundraising by charities. We set ourselves standards that aim to meet or exceed their Code of Fundraising Practice.

FUNDRAISING PERFORMANCE

Our Fundraising revenue has seen a significant increase in the last three years, with an increased number of Mo Bros and Mo Sisters taking part into our Movember campaign and raising funds to support men’s health, including in 2020, despite the Global pandemic. This performance is attributed to a mixture of carefully planned investment in media to raise awareness of Movember’s brand and campaign; efforts to ensure that Campaign activations in 2020 were designed to be agnostic of whether participants were subject to COVID-19 restrictions or not; and a focus on providing opportunities for Campaign participants to connect virtually with Movember and each other in a time where this has become more important than ever.

We have been actively focused on diversifying our fundraising activities beyond our flagship peer to peer campaign in order to secure a sustainable long-term source of revenue, and started to engage in philanthropy and major giving as well as launched a monthly giving trial at the beginning of 2021. This trial saw a good level of engagement from our community but a low level of conversion, prompting us to cut the initial planned investment and review our approach for future campaigns. We are still at the early stages for both activities and are prudently testing and learning from different approaches.

SUPPORTERS’ DATA

Movember maintains a global GDPR compliant privacy policy and business practices that reflect our commitment to being respectful, fair and transparent with Mo Bros, Mo Sisters, employees, partners and authorities about how we collect, use and safeguard personal information.

WORKING WITH THIRD PARTIES

Our Mo Community is key to Movember’s ongoing success, and is at the heart of everything we do, therefore we aim to offer a remarkable experience to every single person that gets in touch with us or gets involved with the campaign in any way. The majority of our fundraising is carried out by our committed Mo Bros and Sisters, growing a moustache, running 60km as a Move challenge, hosting an event, or undertaking their own challenges and raising money whilst doing so from their friends, families and local businesses. Movember does not use professional fundraisers to carry out its fundraising activities.

Movember has a number of arrangements in place with Commercial Participators, including our Corporate Partners. Where these arrangements exist, we ensure that contracts are in place that include a commitment from the Commercial Participator that they will comply with the Fundraising Code of Practice. We maintain a system of monitoring compliance with these requirements, and ensure that any complaints from the public are fed back to us.

We have a specific Commercial Participator agreement in place for the running of the Distinguished Gentleman’s Ride, whereby the Participator organises the event and collects donations on our behalf, in return for a fee. This agreement involves a commitment to comply with the Fundraising Code of Practice, and allows for monitoring and dissemination of any complaints received.

COMPLAINTS

During the reporting period, we received five informal complaints, all of which were satisfactorily addressed and resolved locally. There were no complaints referred from the Fundraising Regulator. We always work to resolve all complaints in a professional and timely manner. We review our Complaints Policy on an annual basis to ensure that we are adopting best practice.

22

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 TRUSTEES’ ANNUAL REPORT

PROTECTING VULNERABLE PEOPLE

Our current fundraising model is primarily based on peer-to-peer donations, and our activities are designed to ensure that no one is put under pressure to donate to us. We are broadening our fundraising strategy and we will continue to review all our safeguarding mechanisms and policies to ensure that we are adopting best practice to protect vulnerable people in all our activities.

PLANS FOR THE FUTURE

In the context of the current COVID-19 pandemic, we continue to focus on supporting our communities through digital resources designed to provide them with practical guidance on how to support the men in their lives who might be struggling, or parenting advice specifically designed for dads. We are also focusing on keeping our fundraising community engaged and, building on the success and key learnings of our 2020 campaign, preparing for delivering our 2021 campaign.

Our ambition for the next three years remains to continue to place our cause and our supporters at the heart of all our fundraising and marketing activities, increasing our focus on mental health and suicide prevention, and to expand the ways in which the public can interact and support our organisation, during and outside our flagship campaign in November. As part of this expansion of fundraising activities, we are continuing to invest in our Major Gift function, working with High Net Worth individuals and Trusts and Foundations. Building on the learnings of our recent monthly giving trial, we are planning a different approach to promote this new way of supporting our cause more prominently, after our main flagship campaign in December 2021. We have also launched a couple of small scale new virtual challenge events in the Spring of 2021 and will build on the insights gathered to scale them in 2022.

As per our Programmes strategy, Movember will continue to invest in Prostate and Testicular Cancer Biomedical Research with our existing partners and Prostate Cancer UK, with this work taking place over multiple years.

Movember will continue to expand our Prostate and Testicular Cancer Survivorship and Clinical Quality work through existing and new partnerships.

With an increased focus on mental health and suicide prevention, Movember will leverage the results of evidence building efforts over the past decade to continue to develop and implement new programmes addressing key at risk populations of men. Movember’s Mental Health programmes are funded over multiple years, enabling the achievement of sustained growth, reach and impact, through an evidence-based behaviour change framework.

23

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 TRUSTEES’ ANNUAL REPORT

STRUCTURE, GOVERNANCE AND MANAGEMENT

Movember Europe is a company limited by guarantee, incorporated on 07/06/2010 and registered as a charity on 10/09/2010. The company was established under a memorandum of association which established the objects and powers of the charitable company and is governed under its articles of association (“Articles”). The single member of Movember Europe is The Movember Group Pty Ltd as trustee for the Movember Foundation Trust (an Australian charitable organisation).

The Articles provide that the business of Movember Europe is to be managed by the Board of Trustees (“Board”). During the 2020/21 year the Board was advised by the following sub-committees:

The Board and its committees are governed by the charters and policies set out in the Movember Governance Policies, including policies in relation to Independence and Conflict of Interests.

All Trustees give their time voluntarily and receive no benefits from the charity. Any expenses reclaimed from the charity are set out in note 7 to the accounts.

Nine Board meetings were held in the 2020/21 financial year. The Finance, Risk and Audit Committee met once, the People & Culture Committee met twice, the Global Scientific Committee met twice, the Global Men’s Health Advisory Committee met three times and the Global Prostate Cancer Outcomes Committee met four times.

The Board is accountable for Movember’s performance; Trustees consider every Mo Bro, Mo Sister, donor, partner and the men that Movember serves as key stakeholders to whom that accountability is owed.

The Board’s primary functions include:

APPOINTMENT AND TRAINING OF TRUSTEES

New Trustees are appointed by the member of Movember Europe on recommendation from the Board. Selection and interviewing for new Trustees is undertaken by an ad-hoc committee of the Board. The primary consideration when selecting new Trustees is to ensure an appropriate balance of skills and experience. Training and induction of Trustees is tailored to the needs of specific incoming Trustees.

24

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 TRUSTEES’ ANNUAL REPORT

RELATED PARTIES AND RELATIONSHIPS WITH OTHER ORGANISATIONS

The Movember Group Pty Ltd as trustee for the Movember Foundation Trust (Movember Europe’s parent), as well as being a registered charity in its own right in Australia, is also the parent of the Movember registered charity organisations in the US (Movember Foundation (US)) and Canada (Movember Canada). The board of Movember Europe has majority control over Movember Foundation e.V. and this entity is therefore treated as a subsidiary entity for consolidation purposes. Each of Movember’s registered charities (in Australia, UK, US, Canada, Germany and New Zealand) are all managed by staff and management based in the relevant country or nearby, but they share central services such as information technology, finance and legal services, which are largely based in the Movember head office in Melbourne, Australia.

Various Trustees that sit on the Board of Movember Europe also sit on the boards of The Movember Group Pty Ltd, Movember Canada, Movember Foundation (US), Movember Foundation e.V. and Movember Foundation NZ.

Movember Europe has a trading subsidiary, Movember Europe Trading Limited. The trading subsidiary was formed in 2011.

REMUNERATION POLICY FOR KEY MANAGEMENT PERSONNEL

Movember utilises the Korn Ferry HayGroup data review for all salaries including the United Kingdom and to provide ongoing market related information. Movember undertakes an annual review of the salary of all staff, including key management personnel and this is benchmarked against an annualised refresh of market data provided by the Korn Ferry HayGroup. As such, we are confident that the salaries we offer our employees are fair and in line with the Not-for-Profit industry in the United Kingdom.

POLICY FOR EMPLOYMENT OF DISABLED PERSONS

Movember’s Workplace Behaviours Policy clearly states that we will abide by all laws in relations to the employment of disabled persons and the policy forbids any discrimination on the grounds of a disability. Any employee found to be discriminating in line with any of the areas named in the above policy, would be subject to formal performance management, which depending on the seriousness may include termination of employment. We use recruitment methods that encourage applications from people with diverse backgrounds and abilities, ensuring all applicants are treated fairly.

EMPLOYEE INFORMATION

All UK based staff have the opportunity to be part of a Pension Scheme. All staff are kept fully informed on the programme and any pension changes announced by the government are communicated to staff through a presentation delivered by a qualified financial advisor, followed by an opportunity provided to all staff for a one-on-one consultation.

We have developed an internal communications strategy and schedule to provide information to staff and seek their feedback. Initiatives to inform staff include updating the intranet with organisational news, information and policies, and providing updates on all areas of the organisation during regular emails from the leadership team and all-staff town halls. There are also weekly work-in-progress meetings in each office, and weekly or fortnightly team meetings.

Staff are frequently encouraged to ask questions and provide feedback informally through their manager or HR team. Formal channels for staff consultation include an annual employee engagement survey and pulse surveys. These surveys cover all areas of the organisation, for example engagement, leadership and development. In 2020 we also conducted surveys on Staff Wellbeing and Diversity, Equity and Inclusion. We report the results back to staff and they have the opportunity to discuss the results within their team meetings. Following this, we create local and global action groups to implement agreed actions. Staff are also provided with the opportunity for an ‘ask me anything’ question and answer session with the leadership team during town halls and when the leadership visit different offices.

Each year we recommend that staff review the organisation’s annual report, which provides information and relevant data regarding the company accounts and financial performance.

All of this is underpinned by a global Human Resources team who are available for any member of the team to confide in on any matter, and access to a free employee assistance programme available 24/7.

25

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 TRUSTEES’ ANNUAL REPORT

STATEMENT OF RESPONSIBILITIES OF THE TRUSTEES

The Trustees (who are also directors of Movember Europe for the purposes of company law) are responsible for preparing the trustees’ annual report including the strategic report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and group and of the incoming resources and application of resources, including the income and expenditure, of the charitable company or group for that period. In preparing these financial statements, the Trustees are required to:

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Trustees are aware:

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company’s website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Members of the charity guarantee to contribute an amount not exceeding £1 to the assets of the charity in the event of winding up. The total number of such guarantees at 30 April 2021 was 10 (2020: 8). The trustees are members of the charity but this entitles them only to voting rights. The trustees have no beneficial interest in the charity.

AUDITOR

Sayer Vincent LLP was re-appointed as the charitable company’s auditor during the year and has expressed its willingness to continue in that capacity.

The Trustees’ annual report which includes the strategic report has been approved by the Trustees on 09 September 2021 and signed on their behalf by

Nicholas Reece Chairperson

26

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 INDEPENDENT AUDITOR’S REPORT

INDEPENDENT AUDITOR’S REPORT

OPINION

We have audited the financial statements of Movember Europe (the ‘parent charitable company’) and its subsidiaries (the ‘group’) for the year ended 30 April 2021 which comprise the consolidated statement of financial activities, the group and parent charitable company balance sheets, the consolidated statement of cash flows and the notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

BASIS FOR OPINION

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

CONCLUSIONS RELATING TO GOING CONCERN

In auditing the financial statements, we have concluded that the trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on Movember Europe’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

27

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 INDEPENDENT AUDITOR’S REPORT

OTHER INFORMATION

The other information comprises the information included in the trustees’ annual report, including the strategic report, other than the financial statements and our auditor’s report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

OPINIONS ON OTHER MATTERS PRESCRIBED BY THE COMPANIES ACT 2006

In our opinion, based on the work undertaken in the course of the audit:

MATTERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION

In the light of the knowledge and understanding of the group and the parent charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees’ annual report, including the strategic report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and Charities Accounts (Scotland) Regulations 2006 (as amended) requires us to report to you if, in our opinion:

RESPONSIBILITIES OF TRUSTEES

As explained more fully in the statement of trustees’ responsibilities set out in the trustees’ annual report, the trustees (who are also the directors of the parent charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the group’s and the parent charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or the parent charitable company or to cease operations, or have no realistic alternative but to do so.

28

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 INDEPENDENT AUDITOR’S REPORT

AUDITOR’S RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS

We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with regulations made under those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud are set out below.

CAPABILITY OF THE AUDIT IN DETECTING IRREGULARITIES

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, our procedures included the following:

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities is available on the Financial Reporting Council’s website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.

29

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 INDEPENDENT AUDITOR’S REPORT

USE OF OUR REPORT

This report is made solely to the charitable company’s members as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005. Our audit work has been undertaken so that we might state to the charitable company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

Noelia Serrano

(Senior statutory auditor) 9 September 2021 for and on behalf of Sayer Vincent LLP, Statutory Auditor Invicta House, 108-114 Golden Lane, LONDON, EC1Y 0TL

Sayer Vincent LLP is eligible to act as auditor in terms of section 1212 of the Companies Act 2006.

30

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING AN INCOME AND EXPENDITURE ACCOUNT)

FOR THE YEAR ENDED 30 APRIL 2021

----- Start of picture text -----
Unrestricted Restricted 2021 Total Unrestricted Restricted 2020 Total
Notes (£) (£) (£) (£) (£) (£)
Income from:
Donations and legacies 2 25,238,674 - 25,238,674 16,684,280 - 16,684,280
Other trading and
charitable activities 3 991,422 564,356 1,555,778 832,141 420,896 1,253,037
Investments 56,598 - 56,598 112,664 - 112,664
Total income 26,286,694 564,356 26,851,050 17,629,085 420,896 18,049,981
Expenditure on:
Raising funds 4 3,211,913 - 3,211,913 3,448,949 - 3,448,949
Charitable activities
Programme
expenditure 4 7,334,316 368,323 7,702,639 10,967,733 492,708 11,460,441
Total expenditure 10,546,229 368,323 10,914,552 14,416,682 492,708 14,909,390
Net income for the year 6 15,740,465 196,033 15,936,499 3,212,403 (71,812) 3,140,591
Transfers between funds (48,164) 48,164 - (47,573) 47,573 -
Net income before other
recognised gains and
losses 15,692,301 244,197 15,936,499 3,164,830 (24,239) 3,140,591
- -
Other gains / (losses) (252,667) (252,667) 247,242 247,242
Net movement in funds 15,439,634 244,197 15,683,831 3,412,072 (24,239) 3,387,833
Reconciliation of funds:
Total funds brought forward 19,040,384 302,115 19,342,499 15,628,312 326,354 15,954,666
Total funds carried forward 34,480,018 546,312 35,026,330 19,040,384 302,115 19,342,499
----- End of picture text -----

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in Note 19 to the financial statements.

31

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021

BALANCE SHEETS

AS AT 30 APRIL 2021

----- Start of picture text -----
The Group The Charity
Notes 2021 (£) 2020 (£) 2021 (£) 2020 (£)
Fixed assets:
Tangible assets 11 118,398 214,847 118,398 214,847
Investments 12 2,500,000 - 2,500,001 1
2,618,398 214,847 2,618,399 214,848
Current assets:
Debtors 15 3,071,568 1,857,846 3,353,022 2,417,569
Short term deposits 11,934,949 5,914,451 11,934,949 5,914,451
Cash at bank and in hand 30,128,838 24,866,331 27,783,029 23,073,358
45,135,356 32,638,627 43,071,000 31,405,378
Liabilities:
Creditors: amounts falling due within
one year 16 12,656,498 13,409,299 12,639,038 13,658,743
Net current assets 32,478,858 19,229,329 30,431,962 17,746,635
Total assets less current liabilities 35,097,255 19,444,176 33,050,361 17,961,483
Creditors: amounts falling due after
one year 17 (70,926) (101,677) (70,926) (101,677)
Total net assets 35,026,330 19,342,499 32,979,435 17,859,807
Funds: 19a
Restricted income funds 546,312 302,115 546,312 302,115
Unrestricted income funds:
Designated funds 27,486,463 11,720,568 25,773,575 10,919,321
General funds 6,993,555 7,319,816 6,659,548 6,638,371
Total unrestricted funds 34,480,018 19,040,384 32,433,123 17,557,692
Total funds 35,026,330 19,342,499 32,979,435 17,859,807
----- End of picture text -----

Approved by the trustees on 9 September 2021 and signed on their behalf by

Nicholas Reece Chairperson

32

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021

CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 30 APRIL 2021

----- Start of picture text -----
Notes 2021 (£) 2020 (£)
Cash flows from operating activities
Net income for the reporting period
(as per the statement of financial activities) 15,936,499 3,140,591
Depreciation charges 104,050 112,300
Dividends, interest and rent from investments (56,598) (112,664)
(Increase) in debtors (1,213,722) (440,687)
(Decrease) in creditors (783,552) (1,110,248)
Net cash provided by operating activities 13,986,677 1,589,292
Cash flows from investing activities:
Dividends, interest and rents from investments 56,598 112,664
Purchase of fixed assets (12,723) (29,632)
Purchase of investments (2,500,000) -
Net cash (used in)/provided by investing activities (2,456,125) 83,032
Cash flows from financing activities:
Amounts (invested)/released in short term deposits (6,020,498) 2,208,417
Net cash (used in)/provided by financing activities (6,020,498) 2,208,417
Change in cash and cash equivalents in the year 5,510,053 3,880,740
Cash and cash equivalents at the beginning of the year 24,866,331 20,738,319
Change in cash and cash equivalents due to exchange
rate movements (247,546) 247,272
Cash and cash equivalents at the end of the year a 30,128,838 24,866,331
----- End of picture text -----

ANALYSIS OF CASH AND CASH EQUIVALENTS AND OF NET DEBT

At 1 May 2020 (£) Cash fows (£) Other non-cash
changes (£)		 At 30 April 2021
(£)
Cash at bank and in hand 24,866,331 5,510,053 (247,546) 30,128,838
a Total cash and cash equivalents 24,866,331 5,510,053 (247,546) 30,128,838

33

MOVEMBER ANNUAL REPORT 2021

NOTES TO THE FINANCIAL STATEMENTS

MOVEMBER EUROPE FOR THE YEAR ENDED 30 APRIL 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 NOTES TO THE FINANCIAL STATEMENTS

1 ACCOUNTING POLICIES

(a) Statutory information

Movember Europe is a charitable company limited by guarantee and is incorporated in England and Wales. The registered office address is Gensurco House, 52-54 Rosebery Avenue, London, England, EC1R 4RP.

Movember Europe is an incorporated charity registered with the Charity Commission for England and Wales, the Office of the Scottish Charity Regulator and the Charities Regulator Ireland.

The registered office address and principal place of business is Gensurco House, 52 - 54 Rosebery Avenue, London, England, EC1R 4RP.

(b) Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) - (Charities SORP FRS 102), The Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

These financial statements consolidate the results of the charity and its wholly-owned subsidiaries Movember Europe Trading Limited and Movember Foundation e.V. on a line by line basis. Transactions and balances between the charity and its subsidiaries have been eliminated from the consolidated financial statements.

Balances between the entities are disclosed in the notes of the charity’s balance sheet. A separate statement of financial activities, or income and expenditure account, for the charity itself is not presented because the charity has taken advantage of the exemptions afforded by section 408 of the Companies Act 2006. As a summary of the result for the year is disclosed in the notes to the accounts.

Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy or note.

In applying the financial reporting framework, the trustees have made a number of subjective judgements, for example in respect of significant accounting estimates. Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The nature of the estimation means the actual outcomes could differ from those estimates. Any significant estimates and judgements affecting these financial statements are detailed within the relevant accounting policy below.

(c) Public benefit entity

The charity meets the definition of a public benefit entity under FRS 102.

(d) Going concern

The Trustees consider that, despite the global challenges resulting from the Covid-19 pandemic, there are no material uncertainties about the charity’s ability to continue as a going concern.

The trustees do not consider that there are any sources of estimation uncertainty at the reporting date that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next reporting period.

(e) Income

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the income have been met, it is probable that the income will be received and that the amount can be measured reliably.

Income received in advance of the provision of a specified service is deferred until the criteria for income recognition are met.

35

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 NOTES TO THE FINANCIAL STATEMENTS

1 ACCOUNTING POLICIES (CONTINUED)

(f) Donations of gifts, services and facilities

Donated professional services and donated facilities are recognised as income when the charity has control over the item or received the service, any conditions associated with the donation have been met, the receipt of economic benefit from the use by the charity of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), volunteer time is not recognised so refer to the trustees’ annual report for more information about their contribution.

On receipt, donated gifts, professional services and donated facilities are recognised on the basis of the value of the gift to the charity which is the amount the charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

(g) Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank.

(h) Fund accounting

Unrestricted funds are donations and other incoming resources received or generated for the charitable purposes.

Restricted funds are to be used for specific purposes as laid down by the donor. Expenditure which meets these criteria is charged to the fund.

Designated funds are unrestricted funds earmarked by the trustees for particular purposes.

(i) Expenditure and irrecoverable VAT

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

Expenditure is classified under the following activity headings:

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

(j) Grants payable

Grants payable are made to third parties in furtherance of the charity’s objects. Single or multi-year grants are accounted for when either the recipient has a reasonable expectation that they will receive a grant and the trustees have agreed to pay the grant without condition, or the recipient has a reasonable expectation that they will receive a grant and that any condition attaching to the grant is outside of the control of the charity.

Provisions for grants are made when the intention to make a grant has been communicated to the recipient but there is uncertainty about either the timing of the grant or the amount of grant payable.

36

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 NOTES TO THE FINANCIAL STATEMENTS

1 ACCOUNTING POLICIES (CONTINUED)

(k) Allocation of support costs

Resources expended are allocated to the particular activity where the cost relates directly to that activity. However, the cost of overall direction and administration of each activity, comprising the salary and overhead costs of the central function, is apportioned on the following basis which are an estimate, based on staff time, of the amount attributable to each activity.

Support and governance costs are re-allocated to each of the activities on the following basis which is an estimate, based on staff time, of the amount attributable to each activity:

Governance costs are the costs associated with the governance arrangements of the charity. These costs are associated with constitutional and statutory requirements and include any costs associated with the strategic management of the charity’s activities.

(l) Operating leases

Rental charges are charged on a straight line basis over the term of the lease.

(m) Tangible fixed assets

Items of equipment are capitalised where the purchase price exceeds £1,000. Depreciation costs are allocated to activities on the basis of the use of the related assets in those activities. Assets are reviewed for impairment if circumstances indicate their carrying value may exceed their net realisable value and value in use. Major components are treated as a separate asset where they have significantly different patterns of consumption of economic benefits and are depreciated separately over its useful life.

Where fixed assets have been revalued, any excess between the revalued amount and the historic cost of the asset will be shown as a revaluation reserve in the balance sheet.

Depreciation is provided at rates calculated to write down the cost of each asset to its estimated residual value over its expected useful life. The depreciation rates in use are as follows:

(n) Investments

Investments in subsidiaries are at cost.

Fixed asset investments include cash balances that are invested in term deposits with a maturity of longer than 12 months.

(o) Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

(p) Short term deposits

Short term deposits includes cash balances that are invested in accounts with a maturity date of between 3 and 12 months.

(q) Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

37

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 NOTES TO THE FINANCIAL STATEMENTS

1 ACCOUNTING POLICIES (CONTINUED)

(r) Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

(s) Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

(t) Foreign exchange

Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the net incoming resources for the year.

(u) Pensions

The charity operated a defined contribution pension scheme. The assets of the scheme are held separately from those of the charity in an independently administered fund. The pension cost charge represents contribution payable and the charity has no other liability under the scheme.

2 INCOME FROM DONATIONS AND LEGACIES

----- Start of picture text -----
Unrestricted (£) 2021 Total (£) Unrestricted (£) 2020 Total (£)
----- End of picture text -----

Donations and Legacies 23,442,345 23,442,345 15,706,664 15,706,664
Gift Aid claimed on donations 1,796,329 1,796,329 977,616 977,616
25,238,674 25,238,674 16,684,280 16,684,280

3 INCOME FROM OTHER TRADING AND CHARITABLE ACTIVITIES

Unrestricted
(£)		 Restricted
(£)		 2021 Total
(£)		 Unrestricted
(£)		 Restricted
(£)		 2020 Total
(£)
Sale of goods (4,350) - (4,350) 127,478 - 127,478
Campaign Partner contributions 970,139 564,356 1,534,495 677,268 420,896 1,098,164
Other 25,633 - 25,633 27,395 - 27,395
991,422 564,356 1,555,778 832,141 420,896 1,253,037

38

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 NOTES TO THE FINANCIAL STATEMENTS

4A ANALYSIS OF EXPENDITURE (CURRENT YEAR)

----- Start of picture text -----
Charitable activities
Raising Programme Governance Support 2021 2020
funds expenditure costs costs Total Total
(£) (£) (£) (£) (£) (£)
-
Staff costs (Note 7) 1,219,399 1,766,148 456,769 3,442,316 3,802,637
Administration 30,170 56,484 - (19,605) 67,050 152,989
Campaign costs and
events 219,196 219,248 - 73 438,516 599,513
Contractors fees 153,197 270,145 - 66,340 489,681 723,001
Entertainment 937 1,568 - 1,187 3,693 15,623
Bank charges 295,540 24,252 - 37,806 357,599 298,991
Insurance 11,647 19,207 - 12,296 43,150 53,061
Legal and professional 16,211 24,446 38,548 13,096 92,301 110,013
IT 49,517 79,129 - 69,848 198,493 229,945
Marketing 856,033 913,482 - 80,353 1,849,867 1,514,969
Depreciation - - - 104,050 104,050 112,300
Travel 617 2,479 - (176) 2,919 226,532
Men's health partner
distributions &
programme delivery
- - -
(Note 5) 3,480,415 3,480,415 6,757,158
Website development
and management 26,689 41,432 - 20,621 88,742 113,488
Building and utilities 27,449 72,020 - 156,290 255,759 199,168
2,906,601 6,970,455 38,548 998,948 10,914,552 14,909,390
Support costs 293,969 704,980 - (998,948) - -
Governance costs 11,344 27,204 (38,548) - - -
Total expenditure 2021 3,211,913 7,702,639 - - 10,914,552
Total expenditure 2020 3,448,949 11,460,441 - - 14,909,390
----- End of picture text -----

Of the total expenditure, £10,546,229 was unrestricted (2020: £14,416,682) and £368,323 was restricted (2020: £492,708).

39

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 NOTES TO THE FINANCIAL STATEMENTS

4B ANALYSIS OF EXPENDITURE (PRIOR YEAR)

----- Start of picture text -----
Charitable activities
Raising Programme Governance Support 2020
funds expenditure costs costs Total
(£) (£) (£) (£) (£)
----- End of picture text -----

Staff costs (Note 7) 1,361,202 1,913,169 - 528,266 3,802,637
Administration 63,828 90,403 - (1,242) 152,989
Campaign costs and events 297,905 299,349 - 2,259 599,513
Contractors fees 255,317 351,668 - 116,016 723,001
Entertainment 5,555 5,435 - 4,633 15,623
Bank charges 258,620 23,932 - 16,439 298,991
Insurance 15,549 22,552 - 14,960 53,061
Legal andprofessional 23,612 35,883 23,788 26,731 110,013
IT 58,756 91,509 - 79,680 229,945
Marketing 689,123 742,442 - 83,405 1,514,969
Depreciation - - - 112,300 112,300
Travel 81,243 115,621 - 29,669 226,532
Men's health partner distributions &
programme delivery (Note 5) - 6,757,158 - - 6,757,158
Website development and management 35,971 52,173 - 25,345 113,488
Buildingand utilities 24,171 35,058 - 139,938 199,168
3,170,851 10,536,353 23,788 1,178,398 14,909,390
Support costs 272,596 905,802 - (1,178,398) -
Governance costs 5,503 18,285 (23,788) - -
Total expenditure 2020 3,448,949 11,460,441 - - 14,909,390

5 MEN’S HEALTH PARTNER DISTRIBUTIONS & PROGRAMME DELIVERY

----- Start of picture text -----
2021 (£) 2020 (£)
----- End of picture text -----

Prostate Cancer UK 602,315 5,236,066
Other European healthpartners 2,076,106 1,385,814
Movember Global Programmes 801,995 135,279
3,480,415 6,757,158

Movember’s organisational strategy has led to a strengthened investment in Mental Health and Suicide Prevention. Investment in Prostate Cancer research programmes was significantly impacted by Covid-19 restrictions in place across the UK and Europe.

40

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 NOTES TO THE FINANCIAL STATEMENTS

6 NET INCOME FOR THE YEAR

This is stated after charging / (crediting):

----- Start of picture text -----
2021 (£) 2020 (£)
----- End of picture text -----

Depreciation 104,050 112,300
Operatinglease rentals:
Property 109,053 97,588
Other 829 3,071
Auditor's remuneration (excludingVAT):
Audit 18,550 18,200
Other services 2,000 1,950
Foreign exchangegains or losses (252,667) 247,242

7 ANALYSIS OF STAFF COSTS, TRUSTEE REMUNERATION AND EXPENSES, AND THE COST OF KEY MANAGEMENT PERSONNEL

Staff costs were as follows:

----- Start of picture text -----
2021 (£) 2020 (£)
----- End of picture text -----

Salaries and wages 1,244,033 1,226,703
Redundancy and termination costs 43,364 -
Social security costs 133,181 127,510
Employer’s contribution to defned contributionpension schemes 42,646 44,834
Recharged staff costs fromparent entity 1,965,659 2,365,472
Other forms of employee benefts 13,433 38,119
3,442,316 3,802,637

Movember Foundation, together with local country affiliates (including Movember Europe), is a global operation with its head office based in Melbourne, Australia. In order to minimise costs in all countries in which the Foundation operates, Movember Foundation charges Movember Europe for its share of certain costs for central services. The services carried out centrally include website development, hosting and maintenance; campaign theme design and related materials; financial and accounting services; human resources services; and general management, including programme implementation and beneficiary partner management services. The costs are charged on actual consumption or, where this cannot be identified, on an equitable basis that is fair to all regions.

The following number of employees received employee benefits (excluding employer pension costs and employer’s national insurance) during the year between:

----- Start of picture text -----
2021 (No.) 2020 (No.)
----- End of picture text -----

£60,000 - £69,999 4 3
£70,000 - £79,999 - -
£80,000 - £89,999 - -
£90,000 - £99,999 1 1

41

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 NOTES TO THE FINANCIAL STATEMENTS

7 ANALYSIS OF STAFF COSTS, TRUSTEE REMUNERATION AND EXPENSES, AND THE COST OF KEY MANAGEMENT PERSONNEL (CONTINUED)

The total employee benefits (including pension contributions and employer’s national insurance) of the key management personnel were £274,039 (2020: £251,693).

Trustees’ expenses represents the payment or reimbursement of travel and subsistence costs incurred by members relating to attendance at meetings of the trustees. There were nil such costs (2020: £nil).

8 STAFF NUMBERS

The average number of employees (head count based on number of staff employed) during the year was 49 (2020: 49).

9 RELATED PARTY TRANSACTIONS

There are no donations from related parties which are outside the normal course of business and no restricted donations from related parties.

Trustees of Movember Europe serve in a voluntary capacity and are not remunerated for their duties as a trustee. One Trustee, Paul Villanti, is also an employee of another Movember Global entity and is remunerated by that related entity for his executive role. The total of this remuneration until his retirement from the Board was £65,271 (2020: £151,053). One Trustee, Nicholas Reece, is remunerated as the Chairperson of Movember Group Pty Limited. The total of his remuneration was £48,386 (2020: nil). The timing of the remuneration received in the financial year ended 30 April 2021 covered a period of 14 months, starting 1 March 2020. The Trustee elected to donate part of his remuneration to Movember Group Pty Limited for an amount of £8,295.

There were no balances outstanding at year end. Remuneration of trustees in an executive capacity is permitted by the Charity’s governing document.

Decisions regarding the remuneration of the above are made by the other members of the trustee board with no input from the affected individuals.

As a member of the global Movember Group, Movember Europe incurs costs on behalf of, and is recharged costs by other members of the Movember Group. A summary of the amounts reallocated between other group entities and Movember Europe and the balance outstanding at the year end is shown below.

----- Start of picture text -----
Expenses Expenses Donation Balance owed to/
reallocated to reallocated from to parent (from) charity at
the charity (£) the charity (£) charity (£) the year end (£)
----- End of picture text -----

Current year
Movember Foundation 4,573,551 4,183,165 - 332,881
Movember Foundation e.V 354,143 62,535 - (8,094)
(Movember Germany)
Movember Europe TradingLtd 133,356 190,293 833,579 869,473
Movember USA 215,492 139,620 - (64,278)
Movember Canada 5,091 254,703 - 80,122
Movember Foundation New Zealand 14,872 18,710 - 988
Prior year
Movember Foundation 4,333,387 3,954,155 - 173,830
Movember Foundation e.V 426,992 155,950 - (279,298)
(Movember Germany)
Movember Europe TradingLtd 262,274 158,547 857,184 853,592
Movember USA 142,891 34,007 - 6,232
Movember Canada 25,686 184,987 - 163,502

42

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 NOTES TO THE FINANCIAL STATEMENTS

10 TAXATION

The charity is exempt from corporation tax as all its income is charitable and is applied for charitable purposes. The charity’s trading subsidiary Movember Europe Trading Limited distributes under gift aid available profits to the parent charity and so no tax is due. Movember Foundation e.V. is a registered association in Germany and is not subject to tax on any surplus generated during the year.

11 TANGIBLE FIXED ASSETS

----- Start of picture text -----
The group and Leasehold Fixtures and Computer Total (£)
the charity improvements (£) fittings (£) equipment (£)
----- End of picture text -----

Cost
At the start of the year 410,915 66,905 210,738 688,558
Additions in year - - 12,723 12,723
Disposals in year - - (7,020) (7,020)
Loss on foreign exchange - (11) (28) (39)
At the end of the year 410,915 66,894 216,413 694,222
Depreciation
At the start of the year 229,658 64,267 179,786 473,711
Charge for the year 82,955 820 20,274 104,050
Eliminated on disposal - - (1,880) (1,880)
Loss on foreign exchange - (13) (44) (57)
At the end of the year 312,613 65,074 198,137 575,824
Net book value
At the end of the year 98,302 1,820 18,276 118,398
At the start of the year 181,257 2,639 30,951 214,847

All of the above assets are used for charitable purposes.

12 INVESTMENTS

Investments are represented by bank term deposits with maturities of greater than one year.

43

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 NOTES TO THE FINANCIAL STATEMENTS

13A SUBSIDIARY UNDERTAKINGS

MOVEMBER EUROPE TRADING LIMITED

The charity owns the whole of the issued ordinary share capital of Movember Europe Trading Limited, a company registered in England. The company number is 7275694. The registered office address is Gensurco House, 52-54 Rosebery Avenue, London, England, EC1R 4RP.

The subsidiary is used for non-primary purpose trading activities. All activities have been consolidated on a line by line basis in the statement of financial activities. Available profits are distributed under Gift Aid to the parent charity.

A summary of the results of the subsidiary is shown below:

----- Start of picture text -----
2021 (£) 2020 (£)
----- End of picture text -----

Turnover 1,036,288 1,015,431
Programme expenditure (75,965) (62,629)
Administrative expenses (29,061) (26,841)
Fundraising (81,027) (70,177)
Proft on ordinary activities before interest and taxation 850,235 855,785
(Loss) /gain on foreign exchange (16,656) 1,399
Proft on ordinary activities before taxation 833,579 857,184
Taxation onproft on ordinary activities - -
Gift aid toparent (833,579) (857,184)
Proft for the fnancial year - -
The aggregate of the assets, liabilities and reserves was:
Assets 875,219 866,755
Liabilities (875,218) (866,754)
Reserves 1 1

Amounts owed to/from the parent undertaking are shown in note 9.

44

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 NOTES TO THE FINANCIAL STATEMENTS

13A SUBSIDIARY UNDERTAKINGS (CONTINUED)

MOVEMBER FOUNDATION E.V. - RESULTS OF OPERATIONS

The charitable company also controls Movember Foundation e.V. an association registered in Germany. The subsidiary is used for carrying out the Movember campaign in Germany. All activities have been consolidated on a line by line basis in the statement of financial activities. A summary of the results of the subsidiary is shown below, the figures are stated using the presentational currency of Euros.

----- Start of picture text -----
2021 (€) 2020 (€)
----- End of picture text -----

Turnover 1,139,482 793,064
Administrative expenses (108,343) (147,922)
Fundraisingcosts (61,659) (79,567)
Men's Health Programmes (310,227) (106,144)
Proft on ordinary activities before interest and taxation 659,252 459,431
(Loss) on foreign exchange (4,634) (827)
Proft on ordinary activities before taxation 654,618 458,604
Taxation onproft on ordinary activities - -
Proft for the fnancial year 654,618 458,604
The aggregate of the assets, liabilities and reserves was:
Assets 2,377,113 1,718,996
Liabilities (23,601) (20,102)
Reserves 2,353,512 1,698,894

13B BRANCHES - MOVEMBER IRELAND - RESULTS OF OPERATIONS

Movember Europe was registered as a charity in Ireland (charity no. 20105280) on 22 March 2018. The activities are not carried out within a separate entity but are instead treated as a branch of the charity. The results of the Ireland operations for the year ended 30 April 2021 were as follows:

----- Start of picture text -----
2021 (€) 2020 (€)
----- End of picture text -----

Revenue 4,946,947 2,153,054
Total costs (760,204) (1,134,829)
Net Income before other recognisedgains and losses 4,186,743 1,018,225
Gain / (loss) on foreign exchange 3,872 (1,033)
Net movement in funds 4,190,614 1,017,192
The aggregate of the assets, liabilities and reserves was:
Assets 6,572,496 2,220,701
Liabilities (490,409) (329,092)
Reserves 6,082,087 1,891,609

45

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 NOTES TO THE FINANCIAL STATEMENTS

14 PARENT CHARITY

The parent charity’s gross income and the results for the year are disclosed as follows:

2021 (£) 2020 (£)
Gross income 25,633,481 17,211,575
Result for the year 15,146,172 2,861,453

15 DEBTORS

----- Start of picture text -----
The group The charity
2021 (£) 2020 (£) 2021 (£) 2020 (£)
----- End of picture text -----

Trade debtors 580,764 282,873 - 7,200
Other debtors 63,859 63,398 63,133 63,398
Gift aid receivable 1,749,542 979,921 1,749,542 979,921
Amounts due fromgroupundertakings 419,940 366,354 1,283,464 1,201,851
Prepayments 93,377 83,363 93,377 83,363
Accrued income 164,086 81,937 163,505 81,837
3,071,568 1,857,846 3,353,022 2,417,569

16 CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

----- Start of picture text -----
The group The charity
2021 (£) 2020 (£) 2021 (£) 2020 (£)
----- End of picture text -----

Men's health partner distribution
payable 11,316,180 12,825,265 11,316,180 12,825,265
Trade creditors 268,379 194,988 266,615 194,988
Taxation and social security 157,129 112,883 142,248 98,839
Other creditors 173,970 217,980 173,970 211,109
Amounts due togroupentities 63,487 - 72,300 279,298
Accruals 677,352 58,183 667,725 49,243
12,656,498 13,409,299 12,639,038 13,658,743

17 CREDITORS: AMOUNTS FALLING DUE AFTER ONE YEAR

The group
2021 (£)
2020 (£)		 The group
2021 (£)
2020 (£)		 The charity
2021 (£)
2020 (£)		 The charity
2021 (£)
2020 (£)
Lease liabilities 70,926 101,677 70,926 101,677
70,926 101,677 70,926 101,677

46

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 NOTES TO THE FINANCIAL STATEMENTS

18A ANALYSIS OF GROUP NET ASSETS BETWEEN FUNDS (CURRENT YEAR)

----- Start of picture text -----
General Designated Restricted Total
unrestricted (£) funds (£) funds (£) funds (£)
Tangible fixed assets 118,398 - - 118,398
----- End of picture text -----

Tangible fxed assets General
unrestricted (£)
118,398		 Designated
funds (£)
-		 Restricted
funds (£)
-		 Total
funds (£)
118,398
Investments 2,500,000 - - 2,500,000
Net current assets 4,446,083 27,486,463 546,312 32,478,858
Longterm liabilities (70,926) - - (70,926)
Net assets at 30 April 2021 6,993,555 27,486,463 546,312 35,026,330

18B ANALYSIS OF GROUP NET ASSETS BETWEEN FUNDS (PRIOR YEAR)

General
unrestricted (£)		 Designated
funds (£)		 Restricted
funds (£)		 Total
funds (£)
Tangible fxed assets 214,847 - - 214,847
Net current assets 7,206,646 11,720,568 302,115 19,229,329
Longterm liabilities (101,677) - - (101,677)
Net assets at 30 April 2020 7,319,816 11,720,568 302,115 19,342,499

19A MOVEMENTS IN FUNDS (CURRENT YEAR)

----- Start of picture text -----
At 1 May Income & Expenditure Transfers At 30 April
2020 (£) gains (£) & losses (£) (£) 2021 (£)
----- End of picture text -----

Restricted funds:
Fero - 86,381 (86,381) - -
L’Oréal 224,014 - (224,014) - -
Mr Porter 16,250 57,853 - 236 74,339
Harlequins 61,851 19,588 (47,928) 47,928 81,439
Gillette - 390,534 - - 390,534
Rugby League World Cup - 10,000 (10,000) - -
Total restricted funds 302,115 564,356 (368,323) 48,164 546,312
Unrestricted funds:
Designated funds:
Men's Health Programme(s) 11,720,568 18,603,555 (2,837,660) - 27,486,463
Total designated funds 11,720,568 18,603,555 (2,837,660) - 27,486,463
General funds 7,319,816 7,683,139 (7,961,236) (48,164) 6,993,555
Total unrestricted funds 19,040,384 26,286,694 (10,798,896) (48,164) 34,480,018
Total funds 19,342,499 26,851,050 (11,167,219) - 35,026,330

The narrative to explain the purpose of each fund is given at the foot of the note below.

47

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 NOTES TO THE FINANCIAL STATEMENTS

19B MOVEMENTS IN FUNDS (PRIOR YEAR)

----- Start of picture text -----
At 1 May Income & Expenditure At 30 April
2019 (£) gains (£) & losses (£) Transfers (£) 2020 (£)
----- End of picture text -----

Restricted funds:
Fero 85,924 87,654 (221,151) 47,573 -
BigHearts 21,500 - (21,500) - -
L'Oréal 218,930 252,641 (247,557) - 224,014
Mr Porter - 16,250 - - 16,250
Harlequins - 61,851 - - 61,851
Rugby League World Cup - 2,500 (2,500) - -
Total restricted funds 326,354 420,896 (492,708) 47,573 302,115
Unrestricted funds:
Designated funds:
Men's Health Programme(s) 9,953,763 3,844,665 (2,077,860) - 11,720,568
Total designated funds 9,953,763 3,844,665 (2,077,860) - 11,720,568
General funds 5,674,549 13,784,420 (12,091,580) (47,573) 7,319,816
Total unrestricted funds 15,628,312 17,629,085 (14,169,440) (47,573) 19,040,384
Total funds 15,954,666 18,049,981 (14,662,148) - 19,342,499

The funds received from Fero are to be utilised within Spain to assist with the funding of the IRONMAN project.

The IRONMAN project is an international, population-based registry of 5,000 men with advanced prostate cancer across ten countries. It seeks to understand clinical outcomes associated with management of advanced prostate cancer and understand the biological and clinical diversity of the disease.

The funds received from Gillette will be used for the delivery of our Veterans and First Responders project, aimed at improving the mental health and wellbeing and preventing suicide of first responders and veterans.

The funds received from L’Oréal will go towards Biomedical research into Prostate and/or Testicular Cancer.

The Mr Porter Health in Mind fund, powered by Movember, will go towards men’s Mental Health initiatives, in accordance with Movember’s mental health strategy.

The funds received from Harlequins and the Rugby League World Cup will be used for delivery of Ahead of the Game, a Movember project aimed at improving youth mental health through community organised sport by engaging with the whole community around the local sports club.

The transfers from general funds to restricted funds, in relation to Mr Porter and Harlequins, represent the recognition of funds received in prior years. The transfer from general funds to restricted funds in FY20, in relation to FERO, represents Movember’s contribution to the IRONMAN project in Spain.

PURPOSES OF DESIGNATED FUNDS

Men’s Health Programme.

This represents funds which the trustees intend to fund all of Movember’s men’s health programmes.

48

MOVEMBER ANNUAL REPORT 2021

MOVEMBER EUROPE REPORT AND FINANCIAL STATEMENTS - FOR THE YEAR ENDED 30 APRIL 2021 NOTES TO THE FINANCIAL STATEMENTS

20 OPERATING LEASE COMMITMENTS PAYABLE AS A LESSEE

The group’s total future minimum lease payments under non-cancellable operating leases is as follows for each of the following periods:

Property
2021 (£)
2020 (£)		 Property
2021 (£)
2020 (£)		 Equipment
2021 (£)
2020 (£)		 Equipment
2021 (£)
2020 (£)
Less than one year 279,294 264,518 1,784 1,784
One to fve years 65,475 327,375 892 2,676
Over fve years - - - -
344,769 591,893 2,676 4,460

21 PARENT COMPANY

The sole member and ultimate parent undertaking is the Movember Foundation, an Australian charitable organisation.

22 LEGAL STATUS OF THE CHARITY

The charity is a company limited by guarantee and has no share capital. The liability of each member in the event of winding up is limited to £1.

49

MOVEMBER ANNUAL REPORT 2021